However, DR3 engagement on IL-33-activated ILC2s only induces the non-canonical NF-κB pathway as evidenced by upregulation of kinase (NIK, encoded by Map3k14), Nfkb2 (p52) and Relb. Furthermore, utilizing a DR3-specific agonist antibody, we establish both a preventative and therapeutic role for DR3 engagement on ILC2s in the context of T2DM. This evidence concerns the gene TNFRSF25 and type 2 diabetes mellitus.